On October 31, 2026, thoracic and gastrointestinal oncology congresses reviewed the expanding clinical paradigms of Enhertu® (Trastuzumab deruxtecan 100 mg injection) by Daiichi Sankyo and AstraZeneca in HER2-mutant non-small cell lung cancer (NSCLC) and locally advanced gastric adenocarcinoma.

Following landmark updates from the DESTINY-Lung02 and DESTINY-Gastric02 Phase 2/3 clinical programs, Enhertu has cemented its role as the undisputed standard of care for patients whose tumors express activating HER2 mutations or HER2 overexpression resistant to conventional chemotherapy.

Through Critical Kare Pharma, certified genuine packs of Enhertu Trastuzumab Deruxtecan 100mg Injection are delivered to oncology clinics worldwide under strict 2°C–8°C validated logistics.

Pharmacology & Bystander Tumor Elimination

• Optimized DAR 8:1: Carries approximately 8 exatecan-derived topoisomerase I inhibitor molecules per monoclonal antibody.
• Membrane-Permeable Cleavable Payload: Released DXd diffuses into neighboring tumor cells, eradicating heterogeneous HER2-expressing tumors.
• DESTINY-Lung02: 5.4 mg/kg dose demonstrated confirmed 49.0% objective response rate in HER2-mutant metastatic NSCLC.

Monitoring for Interstitial Lung Disease (ILD)

Mandatory pulmonary vigilance: immediate chest CT and systemic corticosteroid intervention upon early signs of cough, dyspnea, or fever.

Global Sourcing Pathways

Available through Critical Kare Pharma via US FDA PIP, UK MHRA, EU EMA, and Middle East health authority import pathways.